Cipla to launch innovative inhaler soon

11 Aug 2015 Evaluate

Cipla will soon launch an innovative inhaler which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). The new inhaler is called Synchrobreathe which is a novel, breath-actuated inhaler (BAI) with a dose counter.

At the South Africa Thoracic Society (SATS) Conference in Cape Town, South Africa (7-10 August 2015) around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists heard about Cipla’s innovation in caring for patients with Obstructive Airway Disease.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes over 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1403.90 4.55 (0.33%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.